Video

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

In this study, the standard dose of IV rituximab was concentrated 12 fold, to 120 mg/ml and mixed with a naturally occurring enzyme which allows it to be injected at volumes that would otherwise be difficult to administer, says Barrett.

The injection takes only six minutes, compared with a two to four hour infusion. Complete and overall response rates and toxicity were comparable between the two administration methods.

<<<

View more from the 13th International Conference on Malignant Lymphoma

Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec